Research notes

The report includes Indo Count in a Textile & Apparel basket with a 20% weightage and a 12-month 15-20% upside target for the basket.

The report includes Pearl Global in a Textile & Apparel basket with a 20% weightage and a 12-month 15-20% upside target for the basket.

The report includes Arvind in a Textile & Apparel basket with a 20% weightage and a 12-month 15-20% upside target for the basket.

The report includes Welspun Living in a Textile & Apparel basket with a 20% weightage and a 12-month 15-20% upside target for the basket.

The report recommends BUY on Divi's Laboratories with CMP ₹9,540, TP ₹10,800 and SL ₹8,870, citing peptide API demand from oral Wegovy, favorable US tariff clarity under Proclamation 11020, and expected 21% earnings CAGR over FY26-28.

The report gives a Buy view on Trent with CMP INR 2,580 and TP INR 3,775, citing 22.5% YoY 2QFY27 standalone revenue growth driven by store expansion and easing cannibalization, with FY26-29E revenue/EBITDA/PAT CAGR of 21%/26%/19%.

The report initiates coverage on Molbio Diagnostics with a BUY rating, CMP INR 1,503 and TP INR 1,800, citing its Truenat platform, 12,500+ devices in 90+ countries, and an estimated 23% revenue CAGR and 50% PAT CAGR over FY26-29.

The report states Shiva Cement, JSW Cement's listed subsidiary, will merge into JSW Cement, with Shiva shareholders getting 5 JSW Cement shares for every 41 Shiva shares.

The report notes hikes in long product, flat steel and alloy steel round bar prices effective 1 Oct'26, with a Positive view.

The report states IndusInd Bank's 2QFY27 net advances grew 11.2% YoY beating estimates while deposits rose 10.1% YoY missing estimates, with CASA ratio falling to 28.0% and FCNR(B) mobilization of USD3.51b supporting growth, with a Positive view.

The report states Axis Bank's 2QFY27 gross advances grew 22.7% YoY beating estimates while deposits grew 20.7% YoY missing estimates, with CASA mix falling to 36.5% and CD ratio rising to 95.4%, with a Positive view.

The report notes Kotak's 2QFY27 net advances grew 24.7% YoY and deposits 23.2% YoY, both above estimates, with CASA ratio falling to 38.2% and CD ratio easing to 88.6%, and states the view as Positive.

The technical snapshot lists the stock as a bearish intraday view at a CMP of 3,558.8 with support at 3,488 and resistance at 3,594.

The technical snapshot lists the stock as a bullish intraday view at a CMP of 557 with support at 551 and resistance at 568.

The note says the company expects exports to remain at 15%-20% of revenue while domestic business continues growing 14%-15%.

The note says the company signed a master restructuring agreement with National Asset Reconstruction Co, with outstanding debt at Rs 3,736 crore.

The note says the company launched eight ayurvedic healthcare and wellness products.

The note says the company partnered with MSN to launch Riociguat Tablets in the US for treatment of recurrent CTEPH.

The note says arm ACME Renewtech commissioned an additional 66.68 MW of solar capacity at Bikaner, taking commissioned capacity to 133.36 MW of a 300 MW hybrid project.

The note says the company has added 1,694 MW of capacity since April, taking total installed capacity to 15.1 GW.

The note says the company signed a binding MoU with Imagicaaworld Entertainment to acquire a Khopoli hotel for Rs 248 crore.

The note says the company entered an operations and management agreement with Mission of Mercy Hospital & Research Centre and that its Girinagar Hospital, Bengaluru commenced commercial operations.

The note says the company received a Rs 73 crore HTLS reconductoring order from Power Grid.

The note says Q2 total average deposits rose 18.8% YoY to Rs 6.06 lakh crore, net average advances rose 22.1% YoY to Rs 5.47 lakh crore and average CASA rose 14.2% YoY to Rs 2.26 lakh crore.

The technical section rates KALYANKJIL as BULLISH intraday with CMP 557, support 551 and resistance 568.